Abstract GS6-04: Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, breast cancer progression, and HER2 inhibitor sensitivity
Abstract
Activating mutations in HER2 (ERBB2) drive the growth of a subset of breast cancers. The HER2 tyrosine kinase inhibitor (TKI) neratinib has shown clinical activity against cancers harboring HER2 activating mutations. Co-occurring HER2 and HER3 (ERBB3) mutations have been reported to co-occur in patients with breast cancer, suggesting the possibility of cooperativity of both oncogenes. Interrogation of the Project GENIE database revealed that...
Paper Details
Title
Abstract GS6-04: Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, breast cancer progression, and HER2 inhibitor sensitivity
Published Date
Feb 15, 2020
Journal
Volume
80
Issue
4_Supplement
Pages
GS6 - 04
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History